{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T14:17:44Z","timestamp":1787840264178,"version":"build-2784847793"},"reference-count":16,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,3]]},"abstract":"<jats:title>Abstract:<\/jats:title>\n                  <jats:sec>\n                    <jats:title>INTRODUCTION:<\/jats:title>\n                    <jats:p>Deferasirox is a newer oral iron chelator which needs to be given for at least 1 year to see a significant decrease in serum ferritin level in thalassemia patients with chronic iron overload. This study aimed to assess the safety profile of branded generic deferasirox in pediatric thalassemia cases, as it has not been studied in eastern India, especially in real-world settings.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>SUBJECTS AND METHODS:<\/jats:title>\n                    <jats:p>It was an observational hospital-based study in a government tertiary care teaching hospital where branded generic deferasirox is distributed free of cost to patients. One hundred and seventy-four patients were included. Safety assessment was done through active questioning about the symptoms starting after deferasirox therapy and through laboratory parameters and clinical examination.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS:<\/jats:title>\n                    <jats:p>Sixty percent of patients developed adverse drug reactions (ADRs) with deferasirox during the 1-year follow-up. ADRs were more common in males than females. The highest number of ADRs was related to the gastrointestinal and hepatobiliary system. The ADRs were either mild or moderate. Compliance and number of ADRs were found to be inversely correlated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION:<\/jats:title>\n                    <jats:p>ADRs of deferasirox are acceptable looking at the benefits. Regular monitoring and management of ADRs will facilitate patient compliance. However, healthcare professionals need to be alert while prescribing this drug and report any ADR, even if it is not labeled. This study found increased serum lipase and mouth ulcer as adverse effects, which are not yet labeled. These can be signals for further analysis by regulatory authorities.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/ijp.ijp_88_23","type":"journal-article","created":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T03:00:11Z","timestamp":1749783611000},"page":"77-82","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Targeted active surveillance of branded generic deferasirox in pediatric thalassemia patients in a tertiary care hospital of India: A pharmacovigilance study"],"prefix":"10.4103","volume":"57","author":[{"given":"Mousumee","family":"Panigrahi","sequence":"first","affiliation":[{"name":"Department of Pharmacology, AIIMS, Gorakhpur, Uttar Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trupti Rekha","family":"Swain","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, S.C.B. Medical College, Cuttack, Odisha, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rabindra Kumar","family":"Jena","sequence":"additional","affiliation":[{"name":"Department of Clinical Haematology, S.C.B. Medical College, Cuttack, Odisha, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashutosh","family":"Panigrahi","sequence":"additional","affiliation":[{"name":"Department of Haemato-Oncology, AIIMS, Bhubaneswar, Odisha, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nishant","family":"Debta","sequence":"additional","affiliation":[{"name":"Dr. Nishant Debta Polyclinic and Diagnostic Centre, Bargarh, Odisha, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,6,13]]},"reference":[{"key":"R1-20250613","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1056\/NEJM199409013310903","article-title":"Survival in medically treated patients with homozygous beta-thalassemia","volume":"331","author":"Olivieri","year":"1994","journal-title":"N Engl J Med"},{"key":"R2-20250613","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1056\/NEJM199409013310902","article-title":"Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major","volume":"331","author":"Brittenham","year":"1994","journal-title":"N Engl J Med"},{"key":"R3-20250613","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1056\/NEJMra050436","article-title":"Beta-thalassemia","volume":"353","author":"Rund","year":"2005","journal-title":"N Engl J Med"},{"key":"R4-20250613","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/S0022-3476(88)80375-5","article-title":"Deferoxamine-induced growth retardation in patients with thalassemia major","volume":"113","author":"De Virgiliis","year":"1988","journal-title":"J Pediatr"},{"key":"R5-20250613","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1111\/j.1600-0609.1988.tb00198.x","article-title":"High-dose desferrioxamine as a cause of growth failure in thalassemic patients","volume":"40","author":"Piga","year":"1988","journal-title":"Eur J Haematol"},{"key":"R6-20250613","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1097\/00043426-199221000-00007","article-title":"Growth failure and bony changes induced by deferoxamine","volume":"14","author":"Olivieri","year":"1992","journal-title":"Am J Pediatr Hematol Oncol"},{"key":"R7-20250613","doi-asserted-by":"crossref","first-page":"172","DOI":"10.4103\/ijp.IJP_68_18","article-title":"Effectiveness of deferasirox in pediatric thalassemia patients:Experience from a tertiary care hospital of Odisha","volume":"52","author":"Panigrahi","year":"2020","journal-title":"Indian J Pharmacol"},{"key":"R11-20250613","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1182\/blood.V89.3.739","article-title":"Iron-chelating therapy and the treatment of thalassemia","volume":"89","author":"Olivieri","year":"1997","journal-title":"Blood"},{"key":"R12-20250613","first-page":"461","article-title":"IAP policy on age of children for pediatric care","volume":"36","author":"John","year":"1999","journal-title":"Indian Pediatr"},{"key":"R14-20250613","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1182\/blood-2002-10-3280","article-title":"Safety and effectiveness of long-term therapy with the oral iron chelator deferiprone","volume":"102","author":"Cohen","year":"2003","journal-title":"Blood"},{"key":"R15-20250613","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1111\/j.1365-2141.1992.tb06445.x","article-title":"Long-term assessment of efficacy and safety of L1, an oral iron chelator, in transfusion dependent thalassaemia:Indian trial","volume":"82","author":"Agarwal","year":"1992","journal-title":"Br J Haematol"},{"key":"R16-20250613","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1111\/j.1600-0609.2004.00377.x","article-title":"Safety of oral iron chelator deferiprone in young thalassaemics","volume":"74","author":"Naithani","year":"2005","journal-title":"Eur J Haematol"},{"key":"R18-20250613","doi-asserted-by":"crossref","first-page":"3455","DOI":"10.1182\/blood-2005-08-3430","article-title":"Aphase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia","volume":"107","author":"Cappellini","year":"2006","journal-title":"Blood"},{"key":"R19-20250613","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1111\/j.1600-0609.2009.01228.x","article-title":"Efficacy and safety of deferasirox, an oral iron chelator, in heavily iron-overloaded patients with beta-thalassaemia:The ESCALATOR study","volume":"82","author":"Taher","year":"2009","journal-title":"Eur J Haematol"},{"key":"R20-20250613","first-page":"1343","article-title":"Phase II clinical evaluation of deferasirox, a once-daily oral chelating agent, in pediatric patients with beta-thalassemia major","volume":"91","author":"Galanello","year":"2006","journal-title":"Haematologica"},{"key":"R21-20250613","doi-asserted-by":"crossref","first-page":"3183","DOI":"10.1182\/blood.V118.21.3183.3183","article-title":"Deferasirox safety profile in patients with transfusion-dependent anaemias:Results from the interim analysis of a Hellenic study","volume":"118","author":"Ladis","year":"2011","journal-title":"Blood"}],"container-title":["Indian Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/ijp.ijp_88_23","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T13:18:51Z","timestamp":1787836731000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ijp.ijp_88_23"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":16,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.4103\/ijp.ijp_88_23","relation":{},"ISSN":["0253-7613","1998-3751"],"issn-type":[{"value":"0253-7613","type":"print"},{"value":"1998-3751","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"2023-02-17","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-05-15","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}